Dr. Marty Makary, the FDA’s commissioner, said the program targets “dead time,” or about half the time between the launch of phase one clinical trials and applications to the FDA at the end of the ...
The U.S. Food and Drug Administration (FDA) is moving to speed drug development and review by launching real-time clinical trials. The move could soon mean more options for patients who need ...
Last week, the U.S. Food and Drug Administration (FDA) published a draft guidance on the use of data monitoring committees (DMCs) in clinical trials entitled “Use of Data Monitoring Committees in ...
The US Food and Drug Administration has begun a pilot program to monitor clinical trials in real time, starting with two oncology studies from AstraZeneca and Amgen. Using Paradigm Health’s data ...
We collaborate with the world's leading lawyers to deliver news tailored for you. Sign Up for any (or all) of our 25+ Newsletters. Some states have laws and ethical rules regarding solicitation and ...
A major shift in FDA’s current thinking, in comparison with the 2006 guidance, is heightened emphasis in the Agency’s view that DMC assessment of interim safety data alone is not sufficient. FDA ...
WASHINGTON--(BUSINESS WIRE)--Today, ACRO’s RBQM Working Group has announced the publication of its latest RBM/RBQM paper, Risk-Based Quality Management: A Case for Centralized Monitoring, in DIA’s ...
The US Food and Drug Administration (FDA) on Tuesday issued final guidance meant to assist drug and medical device makers in developing risk-based monitoring strategies for clinical investigations ...
The U.S. Food and Drug Administration has begun a pilot program to monitor clinical trial data in real time, aiming to cut years from drug approval timelines. AstraZeneca and Amgen are running ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results